Retension Pharmaceuticals, Inc. — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Retension Pharmaceuticals, Inc. filed a Third Amended and Restated Certificate of Incorporation effective October 13, 2026. Key changes include: (1) authorization of 500M total shares (490M common, 10M preferred) with par value $0.0001; (2) elevation of director removal threshold to 66.67% supermajority vote; (3) elevation of bylaw amendments to 66.67% supermajority; (4) establishment of exclusive Delaware Chancery Court forum for internal corporate claims and federal court forum for Securities Act claims; (5) board power to set director count by resolution. No dollar amounts, counterparties, or dates of effectiveness beyond October 13, 2026 are specified. Prior amendments were filed April 17, 2025 and October 2, 2026.
Why this rating
Standard corporate governance restructuring: supermajority protections are typical defensive measures, not uncommon for early-stage biotech. No financing, M&A, or operational change disclosed. Company scale unknown but filing format suggests small/early-stage; governance amendments alone are routine.
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.